EA200600701A1 - Соли и полиморфные формы эффективного антидиабетического соединения - Google Patents

Соли и полиморфные формы эффективного антидиабетического соединения

Info

Publication number
EA200600701A1
EA200600701A1 EA200600701A EA200600701A EA200600701A1 EA 200600701 A1 EA200600701 A1 EA 200600701A1 EA 200600701 A EA200600701 A EA 200600701A EA 200600701 A EA200600701 A EA 200600701A EA 200600701 A1 EA200600701 A1 EA 200600701A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
polymorphic forms
polymorphs
effective anti
compound
Prior art date
Application number
EA200600701A
Other languages
English (en)
Other versions
EA013367B1 (ru
Inventor
Генри Т. Крак
Лоренс Р. Маги
Бин ЯН
Original Assignee
Эмджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен, Инк. filed Critical Эмджен, Инк.
Publication of EA200600701A1 publication Critical patent/EA200600701A1/ru
Publication of EA013367B1 publication Critical patent/EA013367B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Изобретение описывает соли и полиморфные формы соединения, используемого в лечении воспалительных и метаболических состояний и заболеваний. В частности, изобретение описывает соли и полиморфные формы соединения, которое модулирует экспрессию и/или функцию рецептора, активируемого пероксисомным пролифератором. Соли и полиморфные формы используют для лечения или профилактики состояний и нарушений, связанных с энергетическим гомеостазом, дифференцировкой адипоцитов и воспалением.
EA200600701A 2003-10-03 2004-10-04 Соли и полиморфные формы эффективного антидиабетического соединения EA013367B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50847003P 2003-10-03 2003-10-03
PCT/US2004/032552 WO2005033074A2 (en) 2003-10-03 2004-10-04 Salts and polymorphs of a potent antidiabetic compound

Publications (2)

Publication Number Publication Date
EA200600701A1 true EA200600701A1 (ru) 2006-10-27
EA013367B1 EA013367B1 (ru) 2010-04-30

Family

ID=34421741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600701A EA013367B1 (ru) 2003-10-03 2004-10-04 Соли и полиморфные формы эффективного антидиабетического соединения

Country Status (19)

Country Link
US (2) US7223761B2 (ru)
EP (1) EP1677797B1 (ru)
JP (2) JP5426813B2 (ru)
KR (1) KR101156277B1 (ru)
CN (1) CN1886134A (ru)
AT (1) ATE546142T1 (ru)
AU (1) AU2004278416B2 (ru)
BR (1) BRPI0414957A (ru)
CA (1) CA2540536C (ru)
DK (1) DK1677797T3 (ru)
EA (1) EA013367B1 (ru)
ES (1) ES2386670T3 (ru)
IL (1) IL174728A (ru)
IS (1) IS8378A (ru)
MX (1) MXPA06003313A (ru)
NO (1) NO333002B1 (ru)
NZ (1) NZ546783A (ru)
WO (1) WO2005033074A2 (ru)
ZA (1) ZA200602669B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US9301919B2 (en) * 2005-12-22 2016-04-05 Oakwood Laboratories, Llc Sublimable sustained release delivery system and method of making same
RU2448093C2 (ru) * 2006-09-21 2012-04-20 Пирамал Лайф Сайнсиз Лимитед Производные пиридина для лечения метаболических нарушений, связанных с устойчивостью к действию инсулина или гипергликемией
US20130245024A1 (en) * 2008-03-06 2013-09-19 Dennis Lanfear Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
US20110034380A1 (en) * 2009-08-05 2011-02-10 Dennis Lanfear Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
WO2012040082A2 (en) 2010-09-21 2012-03-29 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MX366765B (es) * 2013-01-30 2019-07-23 Intekrin Therapeutics Inc Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
BR112017019170A2 (pt) 2015-03-09 2018-07-10 Intekrin Therapeutics, Inc. métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
WO2017178408A1 (en) 2016-04-15 2017-10-19 Syngenta Participations Ag Microbiocidal silicon containing aryl derivatives
SG10202101501PA (en) * 2016-08-18 2021-03-30 Intekrin Therapeutics Inc PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS
EA201990513A1 (ru) * 2016-08-18 2019-08-30 Интекрин Терапьютикс, Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ
KR20190064583A (ko) * 2016-09-13 2019-06-10 인테크린 테라퓨틱스, 아이엔씨. Chs-131로 다발성 경화증의 치료
WO2018136635A1 (en) * 2017-01-18 2018-07-26 Coherus Biosciences, Inc. Pparϒ agonist for the treatment of huntington's disease
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物，其药物组合物及其用途
JP2022516509A (ja) 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
US20220193102A1 (en) 2019-04-02 2022-06-23 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220288054A1 (en) 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220288053A1 (en) 2019-04-04 2022-09-15 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205026A1 (en) 2019-04-04 2020-10-08 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205023A1 (en) 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
EP3976037A1 (en) 2019-05-30 2022-04-06 Coherus Biosciences, Inc. Compositions and methods to treat cancer
WO2021076616A1 (en) 2019-10-15 2021-04-22 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2022051318A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a thyroid receptor beta agonist
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
WO2022051319A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a dpp-4 inhibitor
WO2022051323A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a ppar agonist
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407309A (en) 1942-02-04 1946-09-10 Squibb & Sons Inc Chemotherapeutic agents of the sulphonamide type
CH362688A (de) 1957-09-10 1962-06-30 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
NL138933B (nl) 1969-03-26 1973-05-15 Erba Carlo Spa Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking.
US3700773A (en) 1969-06-25 1972-10-24 Merck & Co Inc Substituted phenylsulfamyl salicyclic acids and derivatives thereof in the treatment of inflammation
US3686192A (en) 1971-01-04 1972-08-22 Minnesota Mining & Mfg Substituted pyridine derivatives
US4061642A (en) 1972-06-22 1977-12-06 Cassella Farbwerke Mainkur Ag 2,4,6-Trisubstituted-3-pyridine carboxamides
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4003734A (en) 1974-01-22 1977-01-18 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl-acetamides, -ureas and urea derivatives and herbicidal compositions and methods containing said compounds
CH592411A5 (en) 1974-04-18 1977-10-31 Ciba Geigy Ag Phenoxymethyl- and phenylthiomethyl-pyridine derivs - with insecticidal, acaricidal and plant-growth regulating activity
US4013621A (en) 1975-04-29 1977-03-22 Ciba-Geigy Corporation Substituted sulfonamide derivatives of hindered phenols and stabilized compositions
GB2009146B (en) 1977-11-29 1982-03-24 Ishihara Sangyo Kaisha Sulphonanilide copmouds and herbicidal compositions therof
US4289876A (en) 1978-11-24 1981-09-15 Bristol-Myers Company Antisecretory agents
JPS5579369A (en) 1978-12-13 1980-06-14 Ishihara Sangyo Kaisha Ltd Urea compound, its preparation, and insecticide comprising it
EP0069585B1 (en) 1981-07-06 1985-07-03 EASTMAN KODAK COMPANY (a New Jersey corporation) Color-forming sulfonamidodiphenylamines, photographic elements containing them and corresponding sulfonimide dyes
US4499304A (en) 1981-07-06 1985-02-12 Eastman Kodak Company Color-forming sulfonamidodiphenylamines and corresponding sulfonimide dyes
US4577028A (en) 1981-10-20 1986-03-18 Ciba-Geigy Corporation 5-Haloalkyl-pyridines
US4565568A (en) 1982-06-18 1986-01-21 The Dow Chemical Company Pyridyl(oxy/thio)phenoxy compounds, herbicidal compositions and methods
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4731090A (en) 1983-12-23 1988-03-15 Ciba-Geigy Corporation Process for protecting keratinous material from attack by insects feed on keratin with pyridyloxytrifluoromethanesulfonanilides
US4549901A (en) 1984-02-16 1985-10-29 Stauffer Chemical Company 2-[4-(Substituted aryl)phenoxy]-N-substituted-phenylsulfonyl propionamides having herbicidal properties
FI864138A (fi) 1985-10-16 1987-04-17 Fisons Plc Heterocykliska blandningar.
DE3545570A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate und deren n-oxide, verfahren zu ihrer herstellung und ihre verwendung als zwischenprodukte
US4866079A (en) 1986-03-19 1989-09-12 Ciba-Geigy Corporation N-pyridyloxyphenylisothioureas and the use thereof in pest control
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
AU604771B2 (en) 1986-09-27 1991-01-03 Fisons Plc Pyridinylphenylthio and pyridinylphenylsulphinyl benzimidazone derivatives
JPS646245A (en) 1987-02-20 1989-01-10 Sumitomo Chemical Co Benzylamine derivative, production thereof and germicide containing said derivative as active ingredient
US4670045A (en) 1987-04-07 1987-06-02 The Dow Chemical Company Fungicidal control employing ester derivatives of 4,6-disubstituted 2-pyridinols
GB8724252D0 (en) 1987-10-15 1987-11-18 Ici Plc Fungicides
JPS646245U (ru) 1987-06-30 1989-01-13
JPH01156953A (ja) 1987-09-01 1989-06-20 Hokko Chem Ind Co Ltd ベンゼンスルホンアニリド誘導体および農園芸用殺菌剤
EP0320448B1 (de) 1987-12-07 1994-12-28 Ciba-Geigy Ag 3-Aminobenzoylphenylharnstoffe
DE3823318A1 (de) 1988-07-09 1990-02-22 Bayer Ag (hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
GB8820115D0 (en) 1988-08-24 1988-09-28 Ici Plc Insecticidal compounds
DE3905075A1 (de) 1989-02-18 1990-08-30 Hoechst Ag Benzolsulfonamide und verfahren zu ihrer herstellung
ZA913760B (en) 1990-05-24 1992-02-26 Sumitomo Chemical Co Pyridine derivatives,their production processes and their compounds for control of insect pests
GB9015658D0 (en) 1990-07-17 1990-09-05 Shell Int Research Herbicidal compounds
DE69129611T2 (de) 1990-08-20 1998-12-17 Eisai Co Ltd Sulfonamid-Derivate
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
JP3188286B2 (ja) 1991-08-20 2001-07-16 塩野義製薬株式会社 フェニルメトキシイミノ化合物およびそれを用いる農業用殺菌剤
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
US5643914A (en) 1993-03-02 1997-07-01 Smithkline Beecham Corporation Pharmaceutical pyridine compounds
CA2166413A1 (en) 1993-06-30 1995-01-12 Richard James Arrowsmith Anti-atherosclerotic diaryl compounds
ATE180468T1 (de) 1993-12-27 1999-06-15 Eisai Co Ltd Anthranilsäure derivate
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US5684195A (en) 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (ru) 1994-11-12 1997-12-01 Zeneca Ltd
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US5814646A (en) 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0778267A4 (en) 1995-06-21 2000-04-05 Otsuka Kagaku Kk SULFONAMIDE DERIVATIVES INCLUDING INSECTICIDES, MITICIDES AND NEMATICIDES
EP0788353A1 (en) 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
NZ331941A (en) 1996-02-22 2000-04-28 Tularik Inc Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JPH09255656A (ja) 1996-03-28 1997-09-30 Hiroyoshi Hidaka スルフォンアミド誘導体及びこれを含有する医薬
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6294559B1 (en) 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
JP3243733B2 (ja) 1996-08-07 2002-01-07 雪印乳業株式会社 新規イソキノリン誘導体
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU735137B2 (en) 1997-02-21 2001-07-05 Bayer Intellectual Property Gmbh Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
JP2002518985A (ja) 1997-05-07 2002-06-25 ユニバーシティー・オブ・ピッツバーグ タンパク質イソプレニルトランスフェラーゼの阻害剤
US5981586A (en) 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
EP0995742A4 (en) 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
CA2377309C (en) * 1999-06-30 2010-11-23 Tularik Inc. Compounds for the modulation of ppar.gamma. activity
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
TW533656B (en) 2000-04-07 2003-05-21 Mirae Corp Cooling control system of linear motor
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
NZ523229A (en) * 2000-06-28 2004-10-29 Tularik Inc Quinolinyl and benzothiazolyl PPAR-gamma modulators
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
WO2002051397A1 (fr) 2000-12-22 2002-07-04 Ishihara Sangyo Kaisha, Ltd. Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives
GB2373725A (en) 2001-03-30 2002-10-02 Novartis Ag Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
AU2005221140A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of PPAR (gamma) activity

Also Published As

Publication number Publication date
US8003665B2 (en) 2011-08-23
AU2004278416B2 (en) 2010-04-15
NO20061974L (no) 2006-07-03
WO2005033074A3 (en) 2005-06-16
CA2540536C (en) 2013-07-02
US20050143416A1 (en) 2005-06-30
US7223761B2 (en) 2007-05-29
JP5426813B2 (ja) 2014-02-26
EA013367B1 (ru) 2010-04-30
MXPA06003313A (es) 2006-06-08
AU2004278416A1 (en) 2005-04-14
CA2540536A1 (en) 2005-04-14
KR20060097121A (ko) 2006-09-13
ZA200602669B (en) 2007-07-25
IL174728A0 (en) 2006-08-20
CN1886134A (zh) 2006-12-27
EP1677797B1 (en) 2012-02-22
EP1677797A4 (en) 2009-03-25
DK1677797T3 (da) 2012-06-04
US20070293536A1 (en) 2007-12-20
JP2012097090A (ja) 2012-05-24
NZ546783A (en) 2008-11-28
IL174728A (en) 2011-06-30
EP1677797A2 (en) 2006-07-12
BRPI0414957A (pt) 2006-11-07
NO333002B1 (no) 2013-02-11
WO2005033074A2 (en) 2005-04-14
IS8378A (is) 2006-03-27
KR101156277B1 (ko) 2012-07-05
ES2386670T3 (es) 2012-08-24
JP2007507537A (ja) 2007-03-29
ATE546142T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
EA200600701A1 (ru) Соли и полиморфные формы эффективного антидиабетического соединения
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
WO2005112921A3 (en) Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
EA200700757A1 (ru) Замещённые дипиперидиновые антагонисты ccr2
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
DK1532974T3 (da) Sammensætning, der omfatter 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthsyre, til behandling af dermatologiske lidelser
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
EP2674417A3 (en) Biaryl PDE4 inhibitors for treating inflammation
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
MX2009001327A (es) Compuestos de indol.
TW200602330A (en) Compounds and compositions as PPAR modulators
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
MA31352B1 (fr) Dérivés imidazolidine carboxamide comme modulateurs de p2x7.
DK1861100T3 (da) 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation
WO2010040055A3 (en) Oral pharmaceutical formulations for antidiabetic compounds
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
NO20053714L (no) Aminosyre fenoksyestere
CL2008003027A1 (es) Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.
MA52569B1 (fr) Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant
ZA200709072B (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate

Legal Events

Date Code Title Description
NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): KG

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG